SCHEMBL732383

SCHEMBL732383

C=Cc1ccc2nccc(Cl)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1B Q9Y463 2/20 0.40
NR4A2 P43354 2/20 0.40
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
AXL P30530 1/20 0.38
PRKCI P41743 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.36
TYMS P04818 1/20 0.36
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31731737 0.86 NR4A2 (0.40) NR4A2ALDH1A1MAPTMEN1KMT2A
SCHEMBL5502854 0.82 DYRK1B (0.40) DYRK1BNR4A2ALDH1A1MAPTHPGD
SCHEMBL732379 0.82 ALDH1A1 (0.47) DYRK1BNR4A2ALDH1A1MAPTHPGD
SCHEMBL16289769 0.80 ALDH1A1 (0.38) NR4A2ALDH1A1MAPTHPGDMEN1
SCHEMBL24839312 0.79 MEN1 (0.41) DYRK1BNR4A2ALDH1A1MAPTHPGD
SCHEMBL5050803 0.79 SMN1; SMN2 (0.47) NR4A2ALDH1A1MAPTHPGDMEN1
SCHEMBL5054240 0.76 TGFBR1 (0.43) NR4A2ALDH1A1MAPTHPGDMEN1
SCHEMBL27590619 0.76 DYRK1B (0.43) DYRK1BNR4A2ALDH1A1MAPTHPGD
SCHEMBL30051309 0.75 NR4A2 (0.66) DYRK1BNR4A2ALDH1A1MAPTHPGD
SCHEMBL1888577 0.75 NR4A2 (0.66) DYRK1BNR4A2ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11654147-B2 ALK2 inhibitors and methods for inhibiting BMP signaling THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-05-23 US disclosed
US-11654147-B2 ALK2 inhibitors and methods for inhibiting BMP signaling THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-05-23 US disclosed
US-20230000869-A1 NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2023-01-05 US disclosed
US-11026947-B2 ALK2 inhibitors and methods for inhibiting BMP signaling THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2021-06-08 US disclosed
US-20200179389-A1 NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-06-11 US disclosed
EP-2998296-B1 CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF Shanghai hengrui pharmaceutical co ltd (CN) 2018-03-14 EP disclosed
EP-2998296-B1 CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF Shanghai hengrui pharmaceutical co ltd (CN) 2018-03-14 EP disclosed
US-9637484-B2 Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2017-05-02 US disclosed
US-9637484-B2 Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2017-05-02 US disclosed
US-9637484-B2 Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2017-05-02 US disclosed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US disclosed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US disclosed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US disclosed
US-20080214455-A1 Novel Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-04 US disclosed
EP-1879563-A4 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-07-16 EP disclosed
EP-1879563-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-01-23 EP disclosed
WO-2007136940-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO disclosed
WO-2007136940-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO disclosed
WO-2007103756-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed
WO-2006132739-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200179389-A1 NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING BMPR2, BMP1, BMP2K DYRK1B 1054/4885NR4A2 2365/4885ALDH1A1 4733/4885
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS PI4KA, JAK3, PIK3CD DYRK1B 2025/4885NR4A2 1126/4885ALDH1A1 636/4885
US-20230000869-A1 NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING BMPR2, BMP1, BMP2K DYRK1B 1054/4885NR4A2 2365/4885ALDH1A1 4733/4885
US-11654147-B2 ALK2 inhibitors and methods for inhibiting BMP signaling BMPR2, BMP1, BMP2K DYRK1B 1257/4885NR4A2 1962/4885ALDH1A1 4711/4885
US-20080214455-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 DYRK1B 1810/4885NR4A2 3824/4885ALDH1A1 4089/4885
US-11026947-B2 ALK2 inhibitors and methods for inhibiting BMP signaling BMPR2, BMP1, BMP2K DYRK1B 1257/4885NR4A2 1962/4885ALDH1A1 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.